Position in ABVX
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$32,594,063
New position
Shares Held
244,590
first reported quarter
Ownership
0.280%
of shares outstanding
% of Portfolio
1.25%
of 13F equity value
Holder Rank
#48
of 302 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in ABVX
reported options exposure · as of Jun 30, 2026CallValue
$35,500,464
CallShares
266,400
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Two Seas Capital LP holds $827,767,805 across 6 Biotechnology names. ABVX ranks #6 (3.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
8,475,356 | $299,942,848 | |
| 2 | NKTR |
Nektar Therapeutics
|
3,092,234 | $215,868,855 | |
| 3 | IMVT |
Immunovant, Inc.
|
3,148,505 | $121,311,897 | |
| 4 | ABUS |
Arbutus Biopharma Corp
|
19,095,583 | $91,658,798 | |
| 5 | QURE |
uniQure N.V.
|
1,441,410 | $66,391,344 | |
| 6 | ABVX |
Abivax S.A.
This page
|
244,590 | $32,594,063 |
All Filings in ABVX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $32,594,063 | 244,590 | Shares | Sole | 2026-08-12 | |
| 2026-06-30 | $35,500,464 | 266,400 | Call | Sole | 2026-08-12 | |
| No filing history on record for this holder in this stock. | ||||||